Binding of the potential antitumour agent indirubin-5-sulphonate at the inhibitor site of rabbit muscle glycogen phosphorylase b. Comparison with ligand binding to pCDK2-cyclin A complex.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  European Journal of Biochemistry

• Publication date

  2004-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/J.1432-1033.2004.04173.XPMID 15153119
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.

  2004cited by this paper
• The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age.

  2003cited by this paper
• Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors.

  2003cited by this paper
• Inhibition of glycogen phosphorylase (GP) by CP-91,149 induces growth inhibition correlating with brain GP expression.

  2003cited by this paper
• GSK-3-selective inhibitors derived from Tyrian purple indirubins.

  2003cited by this paper
• Glycogen phosphorylase as a molecular target for type 2 diabetes therapy.

  2002cited by this paper
• Structure-activity analysis of the purine binding site of human liver glycogen phosphorylase.

  2002cited by this paper
• Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy.

  2001cited by this paper
• Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate.

  2001cited by this paper
• The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase.

  2001cited by this paper
• Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?

  2001cited by this paper
• Regulation of Muscle Glycogen Phospfaorylase by Physiological Effectors

  2001cited by this paper
• Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus

  2001cited by this paper
• Flavopiridol Inhibits Glycogen Phosphorylase by Binding at the Inhibitor Site*

  2000cited by this paper
• Structural basis of the synergistic inhibition of glycogen phosphorylase a by caffeine and a potential antidiabetic drug.

  2000cited by this paper
• Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies.

  1999cited by this paper
• Allosteric inhibition of glycogen phosphorylase a by the potential antidiabetic drug 3‐isopropyl 4‐(2‐chlorophenyl)‐1,4‐dihydro‐1‐ethyl‐2‐methyl‐pyridine‐3,5,6‐tricarboxylate

  1999cited by this paper
• Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases

  1999cited by this paper
• Crystallography & NMR system: A new software suite for macromolecular structure determination.

  1998cited by this paper
• Processing of X-ray diffraction data collected in oscillation mode.

  1997cited by this paper
• [20] Processing of X-ray diffraction data collected in oscillation mode.

  1997cited by this paper
• Raster3D: photorealistic molecular graphics.

  1997cited by this paper
• The effect of caffeine and caffeine analogs on rat liver phosphorylase a activity.

  1997cited by this paper
• N‐acetyl‐β‐D‐glucopyranosylamine: A potent T‐state inhibitor of glycogen phosphorylase. A comparison with α‐D‐glucose

  1995cited by this paper
• The CCP4 suite: programs for protein crystallography.

  1994cited by this paper
• Satisfying hydrogen bonding potential in proteins.

  1994cited by this paper
• PROCHECK: a program to check the stereochemical quality of protein structures

  1993cited by this paper
• Evolution of Allosteric Control in Glycogen Phosphorylase

  1993cited by this paper
• Evolution of allosteric control in glycogen phosphorylase.

  1993cited by this paper
• The structure, role, and regulation of type 1 protein phosphatases.

  1992cited by this paper
• Glycogen phosphorylase: control by phosphorylation and allosteric effectors

  1992cited by this paper
• A rapid finite difference algorithm, utilizing successive over‐relaxation to solve the Poisson–Boltzmann equation

  1991cited by this paper
• Improved methods for building protein models in electron density maps and the location of errors in these models.

  1991cited by this paper
• A program to produce both detailed and schematic plots of protein structures

  1991cited by this paper
• The family of glycogen phosphorylases: structure and function.

  1989cited by this paper
• Improved Fourier Coefficients for Maps Using Phases from Partial Structures with Errors

  1986cited by this paper
• Phosphorylase a is an allosteric inhibitor of the glycogen and microsomal forms of rat hepatic protein phosphatase‐1

  1986cited by this paper
• Site-site interactions in glycogen phosphorylase b probed by ligands specific for each site.

  1983cited by this paper
• Analysis of an allosteric binding site: the nucleoside inhibitor site of phosphorylase alpha.

  1982cited by this paper
• Regulation of the dephosphorylation of glycogen phosphorylase a and synthase b by glucose and caffeine in isolated hepatocytes.

  1981cited by this paper
• Synergistic regulation of phosphorylase a by glucose and caffeine.

  1978cited by this paper
• On the treatment of negative intensity observations

  1978cited by this paper
• THE ROLE OF ADENYLIC ACID IN THE ACTIVATION OF PHOSPHORYLASE.

  1964cited by this paper

• Benzimidazole‐oxindole hybrids: A novel class of selective dual CDK2 and GSK‐3β inhibitors of potent anticancer activity

  2024cites this paper
• Outliers in SAR and QSAR: 4. effects of allosteric protein–ligand interactions on the classical quantitative structure–activity relationships

  2022cites this paper
• Improving inverse docking target identification with Z‐score selection

  2019influential citation
• Tetrazoles via Multicomponent Reactions

  2019cites this paper
• Indirubin, a bis-indole alkaloid binds to tubulin and exhibits antimitotic activity against HeLa cells in synergism with vinblastine.

  2018cites this paper
• Computer-Aided Discovery of Glycogen Phosphorylase Inhibitors Exploiting Natural Products

  2017cites this paper
• Phytogenic Polyphenols as Glycogen Phosphorylase Inhibitors: The Potential of Triterpenes and Flavonoids for Glycaemic Control in Type 2 Diabetes.

  2017cites this paper
• Indirubin and Indirubin Derivatives for Counteracting Proliferative Diseases

  2015cites this paper
• Vibrational spectroscopic and molecular docking study of 2-Benzylsulfanyl-4-[(4-methylphenyl)-sulfanyl]-6-pentylpyrimidine-5-carbonitrile, a potential chemotherapeutic agent.

  2015cites this paper
• Spectroscopic investigation (FT-IR, FT-Raman), HOMO-LUMO, NBO analysis and molecular docking study of 2-[(4-chlorobenzyl)sulfanyl]-4-(2-methylpropyl)-6-[3-trifluoromethyl)-anilino]pyrimidine-5-carbonitrile, a potential chemotherapeutic agent.

  2015cites this paper
• Natural products and their derivatives as inhibitors of glycogen phosphorylase: potential treatment for type 2 diabetes

  2014influential citation
• New perspective on the dual functions of indirubins in cancer therapy and neuroprotection.

  2014cites this paper
• Glycogen phosphorylase inhibitors: a patent review (2008 – 2012)

  2013cites this paper
• Physicochemical characterization and in vitro permeation of an indirubin derivative.

  2013cites this paper
• Sourcing the affinity of flavonoids for the glycogen phosphorylase inhibitor site via crystallography, kinetics and QM/MM-PBSA binding studies: comparison of chrysin and flavopiridol.

  2013cites this paper
• Implementation of PLS discriminant analysis to rank indirubin derivatives against decoys

  2013cites this paper
• C-Glikozil heterociklusok előállítása glikogén foszforiláz gátlására

  2013cites this paper
• idTarget: a web server for identifying protein targets of small chemical molecules with robust scoring functions and a divide-and-conquer docking approach

  2012cites this paper
• Differential effects of indirubin and 2,3,7,8-tetrachlorodibenzo-p-dioxin on the aryl hydrocarbon receptor (AhR) signalling in liver progenitor cells.

  2011cites this paper
• Kinetics, in silico docking, molecular dynamics, and MM‐GBSA binding studies on prototype indirubins, KT5720, and staurosporine as phosphorylase kinase ATP‐binding site inhibitors: The role of water molecules examined

  2011cites this paper
• From structure--based to knowledge--based drug design through x-ray protein crystallography: sketching glycogen phosphorylase binding sites.

  2011cites this paper
• Indirubins deplete striatal monoamines in the Intact and MPTP-treated mouse brain and block kainate-induced striatal astrogliosis.

  2010cites this paper
• Recent advances in the allosteric inhibition of glycogen phosphorylase.

  2010cites this paper
• Effect of Indirubin-3´-monoxime on platelet derived growth factor-induced vascular smooth muscle cell migration

  2010cites this paper
• Probing multivalency for the inhibition of an enzyme: glycogen phosphorylase as a case study

  2009cites this paper
• Investigations on the mechanism of allosteric activation of rabbit muscle glycogen phosphorylase b by AMP

  2009cites this paper
• Synthesis and kinase inhibitory activity of novel substituted indigoids.

  2009cites this paper
• Advances in glycogen phosphorylase inhibitor design.

  2008cites this paper
• Determination and pharmacokinetic study of indirubin in rat plasma by high-performance liquid chromatography.

  2008cites this paper
• Indirubin-3'-monoxime, a derivative of a Chinese anti-leukemia medicine, inhibits Notch1 signaling.

  2008cites this paper
• Indirubin-3 0-monoxime , a derivative of a Chinese anti-leukemia medicine , inhibits Notch 1 signaling

  2008cites this paper
• Photoreactivity of indirubin derivatives

  2008cites this paper
• Inhibitors of cyclin dependent kinases: useful targets for cancer treatment.

  2008cites this paper
• New inhibitors of glycogen phosphorylase as potential antidiabetic agents.

  2008cites this paper
• Synthesis of 5-chloro-N-aryl-1H-indole-2-carboxamide derivatives as inhibitors of human liver glycogen phosphorylase a.

  2008cites this paper
• Indirubin-3′-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MAPK

  2007cites this paper
• Sugar-derived Heterocycles and Their Precursors as Inhibitors Against Glycogen Phosphorylases (GP)

  2007cites this paper
• Diversity of the intracellular mechanisms underlying the anti-tumor properties of indirubins

  2007cites this paper
• 7-Bromoindirubin-3′-oxime induces caspase-independent cell death

  2006cites this paper
• Glycogen phosphorylase inhibition as a therapeutic target: a review of the recent patent literature

  2006cites this paper
• Indirubin Enhances Tumor Necrosis Factor-induced Apoptosis through Modulation of Nuclear Factor-κB Signaling Pathway*

  2006cites this paper
• Food chemistry and environmental toxicology

  2006cites this paper
• 3'-Substituted 7-halogenoindirubins, a new class of cell death inducing agents.

  2006cites this paper
• Our senior editors. Gerhard Eisenbrand: food chemistry and environmental toxicology.

  2006cites this paper
• Increased potency and efficacy of combined phosphorylase inactivation and glucokinase activation in control of hepatocyte glycogen metabolism.

  2005cites this paper